Silence Therapeutics plc (SLN)
Automate Your Wheel Strategy on SLN
With Tiblio's Option Bot, you can configure your own wheel strategy including SLN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLN
- Rev/Share 0.185
- Book/Share 1.82
- PB -2.3206
- Debt/Equity 0.0005
- CurrentRatio -8.8138
- ROIC -0.3844
- MktCap 261655768.0
- FreeCF/Share -0.4363
- PFCF -4.2326
- PE -4.5957
- Debt/Assets -0.0003
- DivYield 0
- ROE -0.8749
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SLN | Goldman | -- | Sell | -- | $6 | Feb. 11, 2025 |
| Initiation | SLN | Jefferies | -- | Buy | -- | $40 | Sept. 3, 2024 |
News
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Silence Therapeutics (SLN) points to a 590.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting (“AGM”) in June 2025. “We are thrilled to welcome Tim to the Silence Board,” said Iain Ross, Chairman of the Sil.
Read More
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2024 Earnings Call February 27, 2025 8:00 AM ET Company Participants Gem Hopkins - Vice President, Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Chief R&D Officer Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Richard Law - Goldman Sachs Keay Nakae - Chardan Myles Minter - William Blair Gem Hopkins Good morning and good afternoon, everyone. Thank you for joining us today.
Read More
About Silence Therapeutics plc (SLN)
- IPO Date 2020-09-08
- Website https://www.silence-therapeutics.com
- Industry Biotechnology
- CEO Craig A. Tooman
- Employees 116